Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115698 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Eva Plomer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Afatinib, Crizotinib, ErbB Receptors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We present the case of a 70-year-old never-smoking female patient with epidermal growth factor receptor (EGFR) p.L858R-mutated metastatic non-small cell lung cancer (NSCLC). After three months of first-line treatment with erlotinib, progression occurred and platinum/pemetrexed was initiated, followed by a response for more than two years. After the progression, the molecular testing of a vertebral metastasis revealed a ROS proto-oncogene 1 (ROS1) translocation and a human epidermal growth factor receptor 2 (HER2) p.S310F mutation, in addition to the known EGFR p.L858R mutation. Crizotinib then led to a durable response of 17 months. The molecular retesting of the tumour cells obtained from the recurrent pleural effusion revealed the absence of the ROS1 translocation, whereas the EGFR and HER2 mutations were still present. Afatinib was added to the crizotinib, and the combination treatment resulted in another durable response of more than two years. The patient died more than 7 years after the initial diagnosis of metastatic NSCLC. This case demonstrates that the repeated molecular testing of metastatic NSCLC may identify new druggable genomic alterations that can impact the patient management and improve the patient outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland.
- Faculty of Medicine, University of Bern, Murtenstrasse 11, 3008 Bern, Switzerland.
- Department of Radiology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland.
- Institute of Pathology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland.
ORCID-Profile: Wolfram Jochum, Kira-Lee Koster
Zitieren
APA
Plomer, E., Früh, M., Lauber, A., Demmer, I., Jochum, W., & Koster, K. L. (2024). Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115698
Vancouver
Plomer E, Früh M, Lauber A, Demmer I, Jochum W, Koster KL. Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115698
BibTeX
@article{Plomer2024,
author = {Plomer, Eva and Früh, Martin and Lauber, Arno and Demmer, Izadora and Jochum, Wolfram and Koster, Kira-Lee},
title = {Prolonged Response to Afatinib and Crizotinib in a Rare Case of EGFR-, HER2-, MET- and ROS1-Alterated Lung Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115698}
}
EUVIMED